mercredi 20 septembre 2017

Onco Actu du 20 septembre 2017

3. Prévention

Professor Jack Cuzick: ‘Sitting on the borders between maths and cancer medicine’ [Cancer Research UK]

3.1 Prévention - Tabac

A smoke-free generation? [BMJ]

4.7 Dép., diag. & prono. - Col de l'utérus

HPV screening for cervical cancer – Expert Reaction [Science Media Centre]

HPV screening better at detecting cervical cancer than pap smear, trial shows [The Guardian]

5. Traitements

Bacteria Can Make Tumors Worse [In the Pipeline]

Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer [NCI]

5.12.2 Immunothérapies - CAR-T

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy [Xconomy]

5.12.8 Immunothérapies - Economie

Nivolumab now available for lung cancer after company offers NICE new CDF deal [NICE]

Life-extending lung cancer drug approved [BBC News]

ICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancers [Institute of Cancer Research]

UK backs Opdivo for lung cancer after Bristol-Myers cuts price [Reuters]

5.2 Pharma

Armed with new data, AbbVie, Roche likely to file early for bigger Venclexta use in CLL: analyst [FiercePharma]

Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery [Pfizer]

5.3 Traitements - FDA, EMA, NICE...

Real World Evidence: FDA Commits to Advancing its Use [RAPS]

Highlighting a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) [Novartis]

Novartis's Rydapt wins EU approval for AML, other diseases [Reuters]

5.6 ESMO

ESMO Press Release: ESMO announces new interim Editor-in-Chief of Annals of Oncology [ESMO]

6. Lutte contre les cancers

Cancer patients need better care, not just more technology [Nature]

6.6 Publications

New Feature Alert: Two-Page ORCID Authorization Process [ORCID]

6.9 Controverses

'One-size-fits-all’ threshold for P values under fire [Nature]